CytoDyn Inc.
CYDYDrugs in Pipeline
8
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How CYDY's past catalysts played out
PRO 140
HIV-1-infection
PRO 140 (350 mg)
HIV
Optimized Background Regimen
HIV
Leronlimab
Solid Tumor, Adult
leronlimab 700 mg
Nonalcoholic Steatohepatitis (NASH)
350 mg leronlimab
Metastatic Colorectal Cancer (mCRC)
Leronlimab (700mg)
Coronavirus Disease 2019
PRO 140 (humanized monoclonal antibody to CCR5)
HIV -1 Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRO 140 | Phase 3 | HIV-1-infection | - | - |
PRO 140 (350 mg) | Phase 3 | HIV | - | - |
Optimized Background Regimen | Phase 3 | HIV | - | - |
Leronlimab | Phase 2 | Solid Tumor, Adult | - | - |
leronlimab 700 mg | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
350 mg leronlimab | Phase 2 | Metastatic Colorectal Cancer (mCRC) | - | - |
Leronlimab (700mg) | Phase 2 | Coronavirus Disease 2019 | - | - |
PRO 140 (humanized monoclonal antibody to CCR5) | Phase 2 | HIV -1 Infection | - | - |
Frequently asked questions
What is in CytoDyn Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in CytoDyn Inc.'s (CYDY) pipeline across Phase 3, Phase 2. Its lead program is PRO 140 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CytoDyn Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CytoDyn Inc. (CYDY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CYDY biotech catalysts?→
Add CYDY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CytoDyn Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.